YONG LI to Antineoplastic Agents
This is a "connection" page, showing publications YONG LI has written about Antineoplastic Agents.
Connection Strength
0.362
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
Score: 0.112
-
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374.
Score: 0.085
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
Score: 0.083
-
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci. 2021 Apr; 64(4):534-547.
Score: 0.082